<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03211143</url>
  </required_header>
  <id_info>
    <org_study_id>173HPS16024</org_study_id>
    <nct_id>NCT03211143</nct_id>
  </id_info>
  <brief_title>A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, and Crossover Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of CKD-381 and D027 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to compare Pharmacokinetics, Pharmacodynamics and safety of CKD-381 and D027 in&#xD;
      healty subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, multiple-dose, and crossover study to compare pharmacokinetics,&#xD;
      pharmacodynamics and safety of CKD-381 and D027 in healthy subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Actual">August 28, 2017</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics(Area under the plasma drug concentration-time curve within a dosing interval(AUCÏ„))</measure>
    <time_frame>0h~12 h</time_frame>
    <description>Evaluating PK of Esomeprazole after Multiple dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics(Percent decrease from baseline in integrated gastric acidity for 24-hour interval after 7th dose)</measure>
    <time_frame>Baseline versus Multiple dose during 7days</time_frame>
    <description>Evaluating PD for ambulatory 24hr pH monitor</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TR group&#xD;
Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days&#xD;
Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT group&#xD;
Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days&#xD;
Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-381</intervention_name>
    <description>Test drug: CKD-381</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Esomeprazole 20mg+Sodum bicarbonate 800mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium</intervention_name>
    <description>Reference drug: Nexium</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Esomeprazole magnesium trihydrate 22.3mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 19 aged and 55 aged in healthy adult&#xD;
&#xD;
          2. Body weight more than 55kg in male, 50kg in female&#xD;
&#xD;
          3. Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)&#xD;
&#xD;
          4. If female, must include more than one among the items&#xD;
&#xD;
               -  The menopause(there is no natural menses for at least 2 years)&#xD;
&#xD;
               -  Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or&#xD;
                  other methods of infertility condition&#xD;
&#xD;
          5. If men has sexual life with women of childbearing age, Necessarily he agrees that use&#xD;
             condoms and do not sperm donation until two months during clinical trials and after&#xD;
             the final dosage of investigational products&#xD;
&#xD;
          6. Those who fully understand about this clinical trials after enough hearing, and then&#xD;
             decided to join the clinical trials by themselves and to comply with the precautions&#xD;
             written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have clinically significant disease that hepatobiliary system(severe hepatic&#xD;
             impairment, etc), kidney(severe renal impairment, etc), nervous system, immune system,&#xD;
             respiratory system, endocrine system, hemato-oncology disease, cardiovascular&#xD;
             system(heart failure, etc) or mental illness, or a history of mental disease.&#xD;
&#xD;
          2. Have a gastrointestinal disease history that can effect drug absorption(Crohn's&#xD;
             disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)&#xD;
&#xD;
          3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the&#xD;
             history of Esomeprazole, additives or benzimidazole family&#xD;
&#xD;
          4. Have a history of fructose intolerance, glucose-galactose malabsorbtion or sucrase&#xD;
             isomaltase deficiency&#xD;
&#xD;
          5. Defined by the following laboratory parameters&#xD;
&#xD;
               -  Na&gt;1.5 upper limit of normal range&#xD;
&#xD;
               -  AST, ALT&gt;1.25 upper limit of normal range&#xD;
&#xD;
               -  Total bilirubin&gt;1.5 upper limit of normal range&#xD;
&#xD;
               -  CPK&gt;1.5 upper limit of normal range&#xD;
&#xD;
               -  eGFR(using by MDRD method)&lt;60mL/min/1.73m2&#xD;
&#xD;
               -  Positive for HBV, HCV and HIV by serology test&#xD;
&#xD;
               -  Positive by urine drug abuse test.&#xD;
&#xD;
               -  Sitting SBP &gt; 140mmHg or &lt; 90mmHg, sitting DBP &gt; 90mmHg or &lt; 60mmHg, after 5&#xD;
                  minutes break.&#xD;
&#xD;
          6. Have a history of drug abuse&#xD;
&#xD;
          7. Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days before&#xD;
             the beginning of study treatment but investigator determine that the taking drug&#xD;
             affect this study or could affect the safety of subjects.&#xD;
&#xD;
          8. Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates&#xD;
             etc.) within 30 days.&#xD;
&#xD;
          9. smoker(except the one who have stopped smoking more than 90days before beginning of&#xD;
             study treatment)&#xD;
&#xD;
         10. A heavy caffeine consumer(caffeine&gt;5 cups/day), alcohol consumer(alcohol&gt;210g/week),&#xD;
&#xD;
         11. Taking foods containing grapefruit within 7 days before the beginning of study&#xD;
             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days&#xD;
             before the beginning of study treatment)&#xD;
&#xD;
         12. Subject who treated with any investigational drugs within 90 days before the beginning&#xD;
             of study treatment&#xD;
&#xD;
         13. Previously donate whole blood within 60 days or component blood within 30 days.&#xD;
&#xD;
         14. Pregnant or lactating women.&#xD;
&#xD;
         15. An impossible one who participants in clinical trial by investigator's decision&#xD;
             including laboratory test result or another reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choon Ok Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials center, Yonsei Univ. Health system</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>November 19, 2017</last_update_submitted>
  <last_update_submitted_qc>November 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>CKD-381</keyword>
  <keyword>Nexium</keyword>
  <keyword>Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

